Steven Mah
Stock Analyst at TD Cowen
(2.14)
# 2,725
Out of 4,711 analysts
32
Total ratings
40%
Success rate
7.97%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $47.94 | +20.98% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $27.39 | +13.18% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $10.08 | +1,090.48% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $6.03 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $19.44 | +116.05% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.85 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $3.50 | +185.71% | 1 | Feb 22, 2023 | |
| ME 23andMe Holding Co. | Initiates: Outperform | $120 | $3.27 | +3,569.72% | 1 | Sep 22, 2022 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.99 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $5.28 | +297.73% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $155 | $161.88 | -4.25% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $2.49 | +1,024.50% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $18.34 | +663.36% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.97 | +2,539.59% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $136.02 | +205.10% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.19 | +3,552.97% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $44.84 | +457.54% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $47.94
Upside: +20.98%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $27.39
Upside: +13.18%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $10.08
Upside: +1,090.48%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $6.03
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $19.44
Upside: +116.05%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.85
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $3.50
Upside: +185.71%
23andMe Holding Co.
Sep 22, 2022
Initiates: Outperform
Price Target: $120
Current: $3.27
Upside: +3,569.72%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.99
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $5.28
Upside: +297.73%
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $161.88
Upside: -4.25%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $2.49
Upside: +1,024.50%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $18.34
Upside: +663.36%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.97
Upside: +2,539.59%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $136.02
Upside: +205.10%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.19
Upside: +3,552.97%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $44.84
Upside: +457.54%